Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.
Emergency Department, Hospital de Gandía, Alicante, Spain.
Am J Emerg Med. 2023 Aug;70:1-9. doi: 10.1016/j.ajem.2023.05.005. Epub 2023 May 9.
Both hyperkalemia (HK) and Acute Heart Failure (AHF) are associated with increased short-term mortality, and the management of either may exacerbate the other. As the relationship between HK and AHF is poorly described, our purpose was to determine the relationship between HK and short-term outcomes in Emergency Department (ED) AHF.
The EAHFE Registry enrolls all ED AHF patients from 45 Spanish ED and records in-hospital and post-discharge outcomes. Our primary outcome was all-cause in-hospital death, with secondary outcomes of prolonged hospitalization (>7 days) and 7-day post-discharge adverse events (ED revisit, hospitalization, or death). Associations between serum potassium (sK) and outcomes were explored using logistic regression by restricted cubic spline (RCS) curves, with sK =4.0 mEq/L as the reference, adjusting by age, sex, comorbidities, patient baseline status and chronic treatments. Interaction analyses were performed for the primary outcome.
Of 13,606 ED AHF patients, the median (IQR) age was 83 (76-88) years, 54% were women, and the median (IQR) sK was 4.5 mEq/L (4.3-4.9) with a range of 4.0-9.9 mEq/L. In-hospital mortality was 7.7%, with prolonged hospitalization in 35.9%, and a 7-day post-discharge adverse event rate of 8.7%. Adjusted in-hospital mortality increased steadily from sK ≥4.8 (OR = 1.35, 95% CI = 1.01-1.80) to sK = 9.9 (8.41, 3.60-19.6). Non-diabetics with elevated sK had higher odds of death, while chronic treatment with mineralocorticoid-receptor antagonists exhibited a mixed effect. Neither prolonged hospitalization nor post-discharge adverse events was associated with sK.
In ED AHF, initial sK >4.8 mEq/L was independently associated with in-hospital mortality, suggesting that this cohort may benefit from aggressive HK treatment.
高钾血症(HK)和急性心力衰竭(AHF)均与短期死亡率增加相关,而两者的治疗均可能使另一种情况恶化。由于 HK 与 AHF 之间的关系描述不佳,我们的目的是确定急诊科(ED)AHF 中 HK 与短期结局之间的关系。
EAHFE 登记处招募了来自西班牙 45 个 ED 的所有 ED AHF 患者,并记录了住院期间和出院后的结局。我们的主要结局是全因住院期间死亡,次要结局为住院时间延长(>7 天)和 7 天出院后不良事件(ED 复诊、住院或死亡)。使用受限立方样条(RCS)曲线的逻辑回归探索血清钾(sK)与结局之间的关系,以 sK = 4.0 mEq/L 为参考,根据年龄、性别、合并症、患者基线状态和慢性治疗进行调整。对主要结局进行交互分析。
在 13606 名 ED AHF 患者中,中位(IQR)年龄为 83(76-88)岁,54%为女性,中位(IQR)sK 为 4.5 mEq/L(4.3-4.9),范围为 4.0-9.9 mEq/L。住院期间死亡率为 7.7%,住院时间延长 35.9%,7 天出院后不良事件发生率为 8.7%。调整后的住院期间死亡率从 sK≥4.8(OR=1.35,95%CI=1.01-1.80)到 sK=9.9(8.41,3.60-19.6)稳步增加。高 sK 的非糖尿病患者死亡的可能性更高,而慢性使用盐皮质激素受体拮抗剂则表现出混合效应。住院时间延长或出院后不良事件均与 sK 无关。
在 ED AHF 中,初始 sK>4.8 mEq/L 与住院期间死亡率独立相关,表明该队列可能受益于积极的 HK 治疗。